Independent Director's Performance Report for 2025
I, Zhang Hongying, as an independent director of Zhejiang Xianju Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company"), have strictly followed the regulations and requirements of relevant laws and regulations in 2025, diligently, faithfully, and responsibly performed my duties as an independent director, and protected the overall interests of the Company and the legitimate rights and interests of all shareholders, especially small and medium shareholders. I hereby report on my performance in 2025:
I. Basic Information of Independent Director
1. Personal Work Experience, Professional Background, and Concurrent Positions
I, Zhang Hongying, born in May 1966, am a member of the Communist Party of China, a Chinese national with no permanent overseas residency. I am an internationally registered internal auditor and currently an associate professor and master's supervisor at the School of Accounting, Zhejiang University of Finance and Economics. I have worked at the School of Accounting, Zhejiang University of Finance and Economics since July 1988, serving successively as Deputy Secretary of the General Party Branch, Secretary of the Party Committee, Director of Alumni Affairs, and Director of Social Cooperation. I served as an independent director of the Company from December 2022 to December 2025, an independent director of Nanhua Futures Co., Ltd. from February 2022 to July 2025, an independent director of Zhejiang Oriental Gene Bio-pharmaceutical Co., Ltd. since May 2023, and an independent director of Zhejiang Jingsheng Mechanical & Electrical Co., Ltd. since December 2025.
2. Statement on Circumstances Affecting Independence
In 2025, during my term of office, there were no circumstances affecting my independence as required by the "Administrative Measures for Independent Directors of Listed Companies," the Shenzhen Stock Exchange's "Code of Self-Regulation No. 1 - Standardized Operation of Main Board Listed Companies," and the "Work System for Independent Directors" of the Company.
II. Overview of Independent Director's Performance in 2025
1. Attendance at Board Meetings and Shareholders' Meetings
(1) Attendance at Board Meetings and Voting
In 2025, during my term of office, the Company held six board meetings, three of which were in-person meetings and three were conducted via written voting. I personally attended all of them and did not have any absences or entrust others to attend on my behalf. With a diligent, responsible, objective, and prudent attitude, I carefully reviewed the proposals and related materials for the meetings. After independent analysis and judgment, I voted in favor of all proposals submitted for the board's deliberation, with no opposing or abstaining votes.
(2) Attendance at Shareholders' Meetings
In 2025, during my term of office, the Company held three shareholders' meetings (namely, the 2024 Annual General Meeting, the First Extraordinary General Meeting of 2025, and the Second Extraordinary General Meeting of 2025). I personally attended them and had no absences.
2. Attendance at Board Special Committees and Independent Director Special Meetings
(1) Board Audit Committee
As the convener of the Audit Committee of the Eighth Board of Directors, I organized six meetings in 2025. These meetings deliberated on various proposals including quarterly internal audit reports, annual reports, the 2024 internal control self-assessment report, the special report on the fund-raising for 2024, the confirmation of daily related-party transactions for 2024, the evaluation report on the performance of the accounting firm in 2024 and the audit committee's report on the accounting firm's fulfillment of supervisory duties in 2024, the audit committee's work report for 2024, and the extension of some fund-raising investment projects. Opinions were formed, and some proposals were submitted to the Company's Board of Directors for deliberation. During my term, I continuously followed up on the work of the Company's audit department and external audit institutions, urged them to strictly implement various audit plans, and promoted the progress of audits, effectively playing the key role of the Audit Committee in audit supervision, risk control, and compliance verification.